IIPLA News
Friday, July 24, 2026

China Denies US Allegations That Moonshot AI Misappropriated Anthropic Technology Amid Rising AI Rivalry

Beijing rejects claims of intellectual property theft by Moonshot AI, emphasizing independent AI advancements and condemning politically motivated accusations from the US

IIPLA News Deskanonymous access0 articles left this week
China Denies US Allegations That Moonshot AI Misappropriated Anthropic Technology Amid Rising AI Rivalry

The ongoing technology rivalry between the United States and China has intensified after the Trump administration accused the Chinese artificial intelligence startup Moonshot AI of unlawfully utilizing Anthropic’s proprietary technology to develop its flagship AI model.

These allegations emerged amid claims that Moonshot AI acquired Nvidia AI hardware in violation of US export controls, marking a significant escalation in Washington’s efforts to restrict China’s advancement in cutting-edge AI technologies.

Chinese officials have strongly rejected the accusations, describing them as politically motivated and lacking empirical evidence. They emphasize that China’s AI sector has achieved its progress independently while respecting intellectual property rights in accordance with relevant regulations.

Michael Kratsios, a senior technology official from the Trump administration, elaborated on the US position by stating that intelligence indicates Moonshot AI leveraged Anthropic’s advanced model, Fable, through a technique known as AI distillation. This method involves training new models using outputs generated by more sophisticated systems.

AI distillation can significantly reduce development costs by extracting core functionalities from existing models. However, when done without authorization, it infringes upon intellectual property rights and violates terms of service agreements.

Beijing has dismissed these claims, underscoring its commitment to independent innovation and protection of intellectual property. A spokesperson for the Chinese military in Washington labeled the allegations as unsubstantiated and urged US officials to acknowledge China’s genuine technological advancements rather than undermine its reputation.

The controversy follows Moonshot AI’s recent launch of Kimi K3, a 2.8 trillion parameter business model touted as the world’s largest open-weight AI system. Kimi K3 has become a focal point in discussions about China’s emergence as a formidable competitor in the global AI landscape.

Moonshot AI has highlighted that Kimi K3 improves the conversion of computing power into AI capabilities more efficiently than its predecessors.

In related developments, companies DeepSeek and MiniMax have reportedly conducted over 16 million interactions with Anthropic’s Claude model using nearly 24,000 fake accounts, violating the company’s terms of service.

As of now, Moonshot AI has not issued any public response to the allegations concerning intellectual property misuse.

Despite the dispute, both the United States and China continue to develop commercially viable AI systems. This rivalry is expected to intensify regulatory scrutiny over technology transfers, intellectual property protections, and access to advanced computing hardware.

The unfolding situation underscores the complex interplay between national security concerns, technological innovation, and international trade regulations in the rapidly evolving AI sector.

Share This Article
Ready-to-post copy includes the article link.

China Denies US Allegations That Moonshot AI Misappropriated Anthropic Technology Amid Rising AI Rivalry Tensions between the US and China have escalated following allegations from the Trump administration that Chinese AI startup Moonshot AI illicitly used Anthropic’s proprietary technology. China has firmly denied these c... Read the full IIPLA article: https://iipla.org/news/china-denies-us-allegations-that-moonshot-ai-misappropriated-anthropic-technology-amid-rising-ai-rivalry

Related Coverage

Continue in the newsroom

Back to newsroom
PatentsGlobal

Paul Weiss Expands Life Sciences Practice with Partner Ian Edvalson in San Francisco

Paul, Weiss, Rifkind, Wharton & Garrison has appointed Ian Edvalson as a partner in its San Francisco office, strengthening the firm’s life sciences transactions and intellectual property practices. Edvalson brings extensive experience advising biopharmaceutical and medical technology companies on licensing, collabora…

Friday, August 7, 2026
PatentsGlobal

Mexican Patent Law Overhaul Demands Early Strategic Planning from Applicants

In the first half of 2026, Mexico implemented sweeping patent reforms that significantly alter how patent applications are prepared, filed, and prosecuted. Key changes include a reduction in the number of substantive office actions and a mandated one-year examination timeline, compelling applicants to adopt earlier an…

Friday, August 7, 2026
PatentsGlobal

China Advances Comprehensive Pharmaceutical IP Protection with New Regulatory Frameworks

China’s pharmaceutical sector is rapidly evolving from generic manufacturing to innovative drug development, supported by a robust intellectual property protection system. Key measures including regulatory data protection, patent term extensions, patent linkage mechanisms, and strengthened judicial and administrative…

Friday, August 7, 2026
PatentsGlobal

T&G Global Posts Strong First-Half Results Driven by Premium Apple Sales

T&G Global reported a 2.6% revenue increase to $572.3 million for the six months ending June 30, 2024, led by a 6.1% rise in its Apples division revenue to $550.9 million. Operating profit grew 30% to $11.6 million before impairment adjustments related to the sale of T&G Fresh businesses. The company highlighted signi…

Friday, August 7, 2026